| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
- Advancing a novel oral small molecule in inflammatory bowel disease (IBD), with potential first-in-human trials targeted by end of 2027 |
| 01 Oct 2026 |
8-K: Costs Associated with Exit or Disposal Activities; Regulation FD Disclosure
–Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader program |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
- FHD-909 (LY4050784) Phase 1 dose-escalation trial advancing as planned with non-small cell lung cancer (NSCLC) as the primary target population |
| 24 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 24, 2026, Foghorn Therapeutics Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The following proposals were submitted to the Company’s stockholders at the Annual Meeting: |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
- FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti-PD-1 antibody demonstrates potential for robust and durable regression with anti-tumor immune memory |
| 21 Apr 2026 |
8-K: Regulation FD Disclosure; Other Events
Unique biology Precision therapeutics Broad impact NASDAQ LISTED FHTX April 2026 Exhibit 99.1 |
| 11 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC) |
| 23 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Exhibit 10.1 February 6, 2026 Ryan D. Maynard 254 Canoe Hill Road New Canaan, Connecticut 06840 Dear Ryan: This letter agreement (the “Agreement”) sets forth the terms and conditions of your employment with Foghorn Therapeutics Inc. (the... |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Unique biology Precision therapeutics Broad impact FHTX January 2026 NASDAQ LISTED |
| 04 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On December 3, 2025, the Board of Directors of Foghorn Therapeutics Inc. (the “Company”) appointed Jeff Sacher as Treasurer and interim Chief Financial Officer (“CFO”), effective immediately. The Company is continuing its search for a pe... |
| 07 Nov 2025 |
8-K: Regulation FD Disclosure
November 2025 Unique biology Precision therapeutics Broad impact NASDAQ LISTED FHTX Exhibit 99.1 |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more
Ongoing FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4(BRG1)-mutated cancer remains on track with non-small cell lung cancer (NSCLC) as the primary target population |
| 30 Oct 2025 |
8-K: Regulation FD Disclosure; Other Events
October 30, 2025 Virtual Investor Event Pipeline Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs Exhibit 99.1 |
| 02 Sep 2025 |
8-K: Regulation FD Disclosure
September 2025 Unique biology Precision therapeutics Broad impact NASDAQ LISTED FHTX Exhibit 99.1 |
| 05 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population, is enrolling well and remains on track |
| 01 Jul 2025 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement
Exhibit 10.1 153962565_15 LEASE AGREEMENT THIS LEASE AGREEMENT (this “Lease”) is made this 27th day of June, 2025 (the “Effective Date”), between ARE-MA REGION NO. 77, LLC, a Delaware limited liability company (“Landlord”), and FOGHORN T... |
| 17 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 17, 2025, Foghorn Therapeutics Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). The following proposals were submitted to the Company’s stockholders at the Annual Meeting: |
| 14 May 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate UpdateFHD-909 (LY4050784) advancing in Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary targe... |
| 01 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
CAMBRIDGE, Mass. -- (GLOBE NEWSWIRE) – May 1, 2025 -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expressio... |
| 28 Apr 2025 |
8-K: Regulation FD Disclosure; Other Events
April 2025 Unique biology Precision therapeutics Broad impact NASDAQ LISTED FHTX |
Loading...